Total Payments
$24,375
2024 Payments
$4,304
Companies
52
Transactions
1,040
Medicare Patients
13,452
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$21,799 (89.4%)
Travel$2,009 (8.2%)
Other$245.00 (1.0%)
Research$200.00 (0.8%)
Education$121.44 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $21,799 | 1,021 | 89.4% |
| Travel and Lodging | $2,009 | 4 | 8.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $245.00 | 2 | 1.0% |
| Unspecified | $200.00 | 1 | 0.8% |
| Education | $121.44 | 12 | 0.5% |
Payments by Type
General
$24,175
1,039 transactions
Research
$200.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $2,376 | 151 | $0 (2024) |
| BIOTRONIK NRO, Inc. | $2,058 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,948 | 112 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,661 | 84 | $0 (2024) |
| Boston Scientific Corporation | $1,581 | 42 | $0 (2024) |
| PFIZER INC. | $1,495 | 88 | $0 (2024) |
| Abbott Laboratories | $1,123 | 32 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $985.79 | 47 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $964.28 | 75 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $898.53 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,304 | 108 | BIOTRONIK NRO, Inc. ($1,885) |
| 2023 | $2,921 | 111 | Novartis Pharmaceuticals Corporation ($334.26) |
| 2022 | $2,659 | 118 | Novartis Pharmaceuticals Corporation ($439.99) |
| 2021 | $2,676 | 122 | BOSTON SCIENTIFIC CORPORATION ($403.32) |
| 2020 | $2,675 | 109 | Abbott Laboratories ($438.67) |
| 2019 | $3,530 | 149 | Medtronic Vascular, Inc. ($842.72) |
| 2018 | $2,757 | 150 | Amgen Inc. ($492.84) |
| 2017 | $2,852 | 173 | Amgen Inc. ($539.91) |
All Payment Transactions
1,040 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Medtronic, Inc. | MICRA (Device) | Food and Beverage | In-kind items and services | $30.23 | General |
| Category: Pacemakers | ||||||
| 12/26/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Oncology | ||||||
| 12/18/2024 | AltaThera Pharmaceuticals LLC | Sotalol Hydrochloride (Drug) | Food and Beverage | Cash or cash equivalent | $27.43 | General |
| Category: Cardiovascular | ||||||
| 12/16/2024 | Medtronic, Inc. | MICRA (Device) | Food and Beverage | In-kind items and services | $39.91 | General |
| Category: Pacemakers | ||||||
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $29.84 | General |
| Category: DIABETES | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/27/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $9.92 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | Medtronic, Inc. | MICRA (Device) | Food and Beverage | In-kind items and services | $36.07 | General |
| Category: Pacemakers | ||||||
| 11/19/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $33.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: DIABETES | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $27.93 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/21/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $16.99 | General |
| Category: Coronary | ||||||
| 10/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: DIABETES | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Cardiology | ||||||
| 10/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $4.12 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.68 | General |
| Category: DIABETES | ||||||
| 10/08/2024 | Medtronic, Inc. | MICRA (Device) | Food and Beverage | In-kind items and services | $31.56 | General |
| Category: Pacemakers | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/07/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $35.10 | General |
| Category: Not Applicable | ||||||
| 10/02/2024 | Medtronic, Inc. | LINQ II (Device) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 10/02/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 3,527 | 4,793 | $999,101 | $339,808 |
| 2022 | 28 | 3,467 | 5,174 | $1.1M | $373,225 |
| 2021 | 31 | 3,303 | 4,955 | $962,614 | $354,276 |
| 2020 | 25 | 3,155 | 5,001 | $880,312 | $318,271 |
Total Patients
13,452
Total Services
19,923
Medicare Billing
$1.4M
Procedure Codes
126
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 644 | 783 | $219,240 | $79,291 | 36.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 254 | 990 | $145,579 | $66,483 | 45.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 330 | 341 | $199,208 | $59,425 | 29.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 154 | 172 | $70,176 | $25,420 | 36.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 178 | 178 | $64,080 | $23,235 | 36.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 283 | 292 | $61,311 | $17,037 | 27.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 113 | 127 | $35,330 | $14,129 | 40.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 66 | $13,926 | $6,629 | 47.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 72 | 88 | $19,448 | $6,013 | 30.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 101 | 237 | $20,380 | $5,671 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 40 | $15,680 | $5,664 | 36.1% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 21 | 21 | $19,005 | $4,349 | 22.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 305 | 312 | $14,116 | $3,711 | 26.3% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 88 | 178 | $9,786 | $3,635 | 37.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $6,188 | $2,357 | 38.1% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 125 | 129 | $8,934 | $2,251 | 25.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 37 | 38 | $7,404 | $1,924 | 26.0% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 76 | 81 | $4,722 | $1,727 | 36.6% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2023 | 289 | 295 | $9,026 | $1,620 | 17.9% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 21 | 54 | $6,912 | $1,562 | 22.6% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 26 | 26 | $23,478 | $1,560 | 6.6% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 125 | 129 | $5,985 | $1,494 | 25.0% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 22 | 22 | $4,004 | $1,232 | 30.8% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 75 | 78 | $2,652 | $894.66 | 33.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $2,178 | $881.32 | 40.5% |
About Dr. Eric Lee, MD
Dr. Eric Lee, MD is a Cardiovascular Disease healthcare provider based in Glendale, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982790812.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Lee, MD has received a total of $24,375 in payments from pharmaceutical and medical device companies, with $4,304 received in 2024. These payments were reported across 1,040 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($21,799).
As a Medicare-enrolled provider, Lee has provided services to 13,452 Medicare beneficiaries, totaling 19,923 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Glendale, CA
- Active Since 10/05/2006
- Last Updated 06/29/2015
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1982790812
Products in Payments
- ELIQUIS (Drug) $2,055
- Prospera (Device) $1,885
- ENTRESTO (Drug) $1,380
- Repatha (Biological) $1,291
- BRILINTA (Drug) $1,127
- Corlanor (Drug) $1,075
- XARELTO (Drug) $985.79
- LifeVest (Device) $898.53
- Reveal LINQ (Device) $890.30
- VERQUVO (Drug) $791.20
- JARDIANCE (Drug) $656.62
- LEQVIO (Drug) $567.91
- FARXIGA (Drug) $515.32
- MULTAQ (Drug) $491.50
- LUX-Dx Insertable Cardiac Monitor (Device) $462.19
- Vascepa (Drug) $418.41
- Livalo (Drug) $403.66
- LUX DX (Device) $403.32
- Stivarga (Drug) $331.36
- Edarbi (Drug) $330.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Glendale
John Mckenzie, M.d, M.D
Cardiovascular Disease — Payments: $191,549
Cardiovascular Disease $191,549
Hugo Riffel Dalinger, Md, MD
Cardiovascular Disease — Payments: $150,245
Cardiovascular Disease $150,245
Harry Balian, M.d, M.D
Cardiovascular Disease — Payments: $133,783
Cardiovascular Disease $133,783
Truong Duong, Md, MD
Cardiovascular Disease — Payments: $109,744
Cardiovascular Disease $109,744
Dr. Amir Hedayati-Rad, M.d, M.D
Cardiovascular Disease — Payments: $94,643
Cardiovascular Disease $94,643
Dr. Gordi Khera, Md, MD
Cardiovascular Disease — Payments: $87,731
Cardiovascular Disease $87,731